T cell engager (TCE) score in patients treated with bispecific CD3 TCE in phase I clinical trials

被引：0
|
作者：
Herbel, Noe
Goldschmidt, Vincent
Michot, Jean-Marie
Laparra, Ariane
Geraud, Arthur
Ouali, Kaissa
Danlos, Francois-Xavier
Vuagnat, Perrine
Bernard-Tessier, Alice
Gazzah, Anas
Bahleda, Rastilav
Hollebecque, Antoine
Marabelle, Aurelien
Postel-Vinay, Sophie
Loriot, Yohann
Massard, Christophe
Ribrag, Vincent
Aix, Santiago Ponce
Champiat, Stephane
Baldini, Capucine
机构：
[1] Gustave Roussy, Drug Dev Dept DITEP, Villejuif, France
[2] Gustave Roussy, Dept Interdisciplinaire Org Parcours Patient DIOP, Villejuif, France
[3] Gustave Roussy Inst, Med Oncol Dept, Villejuif, France
[4] Gustave Roussy, Drug Dev Dept, Canc Campus, Villejuif, France
[5] Gustave Roussy, Drug Dev Dept, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2573
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3+tumors: Focus on Asian pts
    Kuboki, Y.
    Gambardella, V.
    Capdevila Castillon, J.
    Alese, O. B.
    Morgensztern, D.
    Sayehli, C. M.
    Sanmamed, M. F.
    Arriola, E.
    Wolf, J.
    Owonikoko, T. K.
    Studeny, M.
    Bouzaggou, M.
    Song, E.
    Wermke, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1495 - S1495
  • [42] Phase I Dose Escalation Trial Of The DLL3/CD3 Igg-Like T Cell Engager BI 764532 In Patients with DLL3+Tumors: Focus on SCLC
    Wermke, M.
    Kuboki, Y.
    Felip, E.
    Alese, O. B.
    Morgensztern, D.
    Sayehli, C.
    Arriola, E.
    Sanmamed, M. F.
    Oum'Hamed, Z.
    Song, E.
    Studeny, M.
    Gambardella, V.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S45 - S46
  • [43] Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
    Laszlo, George S.
    Gudgeon, Chelsea J.
    Harrington, Kimberly H.
    Dell'Aringa, Justine
    Newhall, Kathryn J.
    Means, Gary D.
    Sinclair, Angus M.
    Kischel, Roman
    Frankel, Stanley R.
    Walter, Roland B.
    BLOOD, 2014, 123 (04) : 554 - 561
  • [44] Mesothelin/CD3 Half-Life-Extended Bispecific T-Cell Engager Molecule Shows Specific Tumor Uptake and Distributes to Mesothelin and CD3-Expressing Tissues
    Suurs, Frans, V
    Lorenczewski, Grit
    Bailis, Julie M.
    Stienen, Sabine
    Friedrich, Matthias
    Lee, Fei
    van der Vegt, Bert
    de Vries, Elisabeth G. E.
    de Groot, Derk-Jan A.
    Lub-de Hooge, Marjolijn N.
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (12) : 1797 - 1804
  • [45] A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager Immunotherapies
    Moore, Gregory L.
    Zeng, Veronica G.
    Diaz, Juan E.
    Bonzon, Christine
    Avery, Kendra N.
    Rashid, Rumana
    Qi, Jing
    Nam, Dong Hyun
    Jacinto, Jonathan
    Dragovich, Matthew A.
    Kim, Yoon Kyung
    Balcazar, Karen P.
    Bakhit, Charles G.
    Eivazi, Araz
    Nguyen, Hanh
    Muchhal, Umesh S.
    Szymkowski, David E.
    Desjarlais, John R.
    Hedvat, Michael
    MOLECULAR CANCER THERAPEUTICS, 2025, 24 (03) : 331 - 344
  • [46] Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Westervelt, Peter
    Cortes, Jorge E.
    Altman, Jessica K.
    Long, Meixiao
    Oehler, Vivian G.
    Gojo, Ivana
    Guenot, Jeanmarie
    Chun, Patrick
    Roboz, Gail J.
    BLOOD, 2019, 134
  • [47] A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent in Multiple Myeloma Patients Relapsed and/or Refractory ( RRMM) to Anti-CD38 Monoclonal Antibodies (mAbs)
    Zabaleta, Aintzane
    Blanco, Laura
    Kim, Peter
    Bisht, Kamlesh
    Wang, Hongfang
    Van de Velde, Helgi J.
    Lasa, Marta
    Tamariz-Amador, Luis-Esteban
    Otero, Paula Rodriguez
    San Miguel, Jesus
    Paiva, Bruno
    Martin-Sanchez, Esperanza
    BLOOD, 2023, 142
  • [48] A new strategy for T cell therapy: T cells secreting TCR anti-CD3 bispecific T-cell engager
    Sun, Hanli
    Huang, Jiao
    Zhan, Kai
    Wu, Wanli
    Tang, Xianqing
    Liu, Min
    Guo, Shanshan
    Zheng, Hongjun
    Huang, Yingjie
    Zhong, Shi
    CANCER RESEARCH, 2024, 84 (06)
  • [49] Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab
    Parisi, Rose
    Cowen, Emily A.
    Gu, Stephanie
    Dusza, Stephen
    Pulitzer, Melissa
    Geyer, Mark B.
    King, Amber C.
    Markova, Alina
    LEUKEMIA & LYMPHOMA, 2023,
  • [50] Dermatologic Adverse Events in Acute Lymphocytic Leukemia Patients Treated with Bispecific T-Cell Engager Blinatumomab
    Parisi, Rose
    Cowen, Emily A.
    Gu, Stephanie
    Pulitzer, Melissa
    Geyer, Mark B.
    King, Amber C.
    Markova, Alina
    BLOOD, 2022, 140 : 11583 - 11583
12345